Need help with Investor Relations? Read our latest eBook. Download Now

Westicke Partners IPO Advisory
Strategic Investor Relations
Independent Capital Markets Advice

Mobile Navigation

Westwicke Blog

The Westwicke Blog is designed to deliver information and insights into the ever-changing world of investor relations and the capital markets, with a specific focus on the healthcare industry.

What to Consider When Choosing a Data Room

Posted on July 5th, 2017. Posted by

What to Consider When Choosing a Data Room

At some point during your company’s growth, you will need to share sensitive data with investors and financial professionals by using a data room. In the old days, a data room was just that: a room filled with printed files and reams of paper containing patent descriptions, clinical data, and financial projections.

Today, data rooms are usually virtual. And with hackers increasing their efforts (and their ability) to steal sensitive data, it’s vital you consider security as well as service and convenience as you evaluate data room solutions.

Continue Reading

Going Public? Five Tips From Experts Who’ve Been There

Posted on May 17th, 2017. Posted by

Going Public? Five Tips From Experts Who’ve Been There

With our colleagues at NASDAQ, we recently co-hosted an informational luncheon for private-company CEOs and CFOs on the IPO process. Guest speakers included a life science venture capital investor and a CFO of a company that went public in 2016.

The management teams in the audience for the well-attended event had plenty of questions for our guests, on everything from how to prepare for an IPO to avoiding pitfalls to making the transition to being a public company.

Our speakers had much to say. Below are a few of their most important pieces of advice:

Continue Reading

Six Ways to Make the Most of Dinner with a Research Analyst

Posted on May 3rd, 2017. Posted by

Six Ways to Make the Most of Dinner with a Research Analyst

Dining with one of your analysts can be nerve-racking, but it really doesn’t need to be.

Sharing a meal at a restaurant should make for a less formal meeting than one conducted in a boardroom. The mood should prove to be friendlier and less business-like, and conversations rarely venture deep into the numbers.

Over dinner, analysts frequently probe for “color” related to previously disclosed themes to gather the kind of details that can animate their coverage and talking points for investors.

Continue Reading

What to Do When An Investor Meeting Goes Awry

Posted on March 22nd, 2017. Posted by

What to Do When An Investor Meeting Goes Awry

Throughout my 23 years as an institutional salesperson, I had the pleasure to host many interesting and successful investor meetings.

Very few of those meetings went badly, because I always made a point to educate the companies I was traveling with in advance of the meeting. My goal was to make sure the management team had a complete background on the investor they were meeting and a deep understanding of that investor’s investment process and philosophy. I even tried to ensure that the management team knew about any investor’s personality quirks so they would not get thrown off their game during the meeting. Investors can sometimes try to intentionally rattle management teams in order to get them to say things they were not planning to say.

Continue Reading

Four Considerations For Your Non-Deal Road Show Strategy

Posted on March 15th, 2017. Posted by

Four Considerations For Your Non-Deal Road Show Strategy

There’s never a better time than the present to chart your investor interaction strategy over the coming months. What investors do you still need to meet with this year – including follow-ups to initial meetings you’ve already held, and meetings with new investors with whom you haven’t yet connected?

Do you have plans for which conferences to attend, new KOLs to contact, or for attracting new sell-side research?

Of course, all of this consideration needs to be prioritized within the context of your company’s upcoming catalysts: clinical trial progress, data readouts, product approvals, product launches, potential financings, growth target bogeys, and other various metrics investors will use to gauge your progress.

Continue Reading

Answering Investors’ Awkward Questions: Stick to the Script

Posted on March 8th, 2017. Posted by

Answering Investors’ Awkward Questions: Stick to the Script

When you get a question from an investor or analyst that seems to be from out of left field, it makes you wonder what the underlying intention is. It may be that the questioner is just new to your story.

However, the questioner could also be heavily shorting your company or long your biggest competitor. The question could be awkwardly phrased or come across as a bit sneaky because the investor is trying to get you to elaborate on an answer or provide more detail on a topic than you have in the past.

Continue Reading

Five Tips for Raising Capital Pre-IPO or Acquisition

Posted on January 18th, 2017. Posted by

Five Tips for Raising Capital Pre-IPO or Acquisition

Development-stage healthcare companies typically need to raise money every one to two years. As they grow, they typically attract larger and more varied forms of financing until the time comes for them to either be acquired or go public. Many companies will opt to run a dual-track strategy at such a time to maximize the value that has been created.

But what if the market isn’t quite ready for your IPO, as we saw throughout most of 2016? How can you keep your development engine running while waiting for the right market conditions to make your debut as a public company?

Continue Reading

Tips for Building a Better Investor Relations Plan

Posted on December 20th, 2016. Posted by

Tips for Building a Better Investor Relations Plan

Failing to plan, the old saying goes, is planning to fail. This is certainly true when it comes to your investor relations strategy. Yet even though strategic planning is every bit as important to your IR success as it is for every other part of your business, we find that many companies fail to plan correctly, if they plan at all.

IR planning is about delivering the right story to a well-defined audience, and about refreshing your message in a way that will continue to resonate with investors. Every good annual plan starts with the same question: What do you want to be different at the end of the year? So it’s vital to articulate your goals before formulating a strategy.

Continue Reading

Seven Tips to Help Ensure Successful Biotech Earnings Calls

Posted on December 7th, 2016. Posted by

Seven Tips to Help Ensure Successful Biotech Earnings Calls

Good CEOs and CFOs know that they only get a limited number of interactions with their buy-side and sell-side analysts each year. Analysts are busy people, with perhaps dozens of listed companies under coverage or on their watch lists. An earnings call is thus one of the few times that companies can have the undivided attention of their covering analysts and interested buy-siders. Use that time wisely. Here are some pointers to consider before you host your next biotech earnings call.

Continue Reading

Why Private Companies Should Meet the Buy Side Early

Posted on November 9th, 2016. Posted by

Why Private Companies Should Meet the Buy Side Early

Some people are a little surprised to hear that a decent percentage of our clients at Westwicke are private, venture-backed healthcare companies. “Why,” they ask, “do private companies need investor relations?”

Having spent the majority of my professional career on the buy side at one of the first U.S.-based healthcare crossover firms, I typically respond by saying: “I often wonder why it takes private companies so long before they do reach out to the buy side!”

Continue Reading

1 2 3

READ OUR INSIDER’S GUIDE TO INVESTOR RELATIONS

Click here to download our latest eBook, Westwicke Partners Insider’s Guide to Investor Relations, for our team’s insights on all things IR-related.

LEARN MORE

Our Locations